**Table S1:** GI cancers therapies using medication

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer type** | **Chemotherapy** | **Targeted therapy** | **Immunotherapy** | **Combined therapy** |
| **Pancreatic Cancer** | * Capecitabine
* Fluorouracil
* Gemcitabine
* Irinotecan
* Leucovorin
* Nab-paclitaxel
* Nanoliposomal irinotecan
* Oxaliplatin
 | Cancer with an NTRK fusion:* Larotrectinib
* Entrectinib

BRCA1 or BRCA2 mutation:* Olaparib

Anti-EGFR:* Erlotinib
 | Anti-PD-1 antibodies for treating (MSI-H) or (dMMR) PC:* Pembrolizumab
* Dostarlimab
 | Metastatic PC:* Combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin, called FOLFIRINOX
* Gemcitabine plus nab-paclitaxel
* gemcitabine plus cisplatin, gemcitabine plus capecitabine, or FOLFOX.
* Fluorouracil, nanoliposomal irinotecan, irinotecan
* Gemcitabine, nab-paclitaxel

  |
| **Colorectal Cancer** | * Capecitabine
* Fluorouracil
* Irinotecan
* Oxaliplatin
* Trifluridine/tipiracil
 | Anti-angiogenesis therapy:* Bevacizumab
* Regorafenib
* Ziv-aflibercept
* Ramucirumab

Anti-EGFR:* Cetuximab
* Panitumumab

BRAF inhibitor:* Encorafenib

Cancer with an NTRK fusion:* Larotrectinib
* Entrectinib
 | Anti-PD-1 antibodies:* Dostarlimab (Recurrent or metastatic colorectal cancers that have dMMR)
* Pembrolizumab (fro (MSI-H) or (dMMR) CRC)
* Nivolumab (Metastatic (MSI-H) or (dMMR) CRC)

Combination of immune checkpoint inhibitors:* Nivolumab and ipilimumab (Metastatic (MSI-H) or (dMMR) CRC)
 | Combined targeted therapy for BRAF V600E:* Encorafenib and Cetuximab

Common combined therapies:* 5-FU with leucovorin
* FOLFOX: 5-FU with leucovorin and oxaliplatin
* 5-FU with leucovorin and irinotecan
* Capecitabine with irinotecan

Capecitabine with oxaliplatin |
| **Liver Cancer** |  | Anti-angiogenesis therapy:* Regorafenib
* Ramucirumab
* Bevacizumab
* Ramucirumab

Tyrosine kinase inhibitors* Lenvatinib
* Sorafenib
* Cabozantinib
 | Immune checkpoint inhibitors:* Pembrolizumab
* Nivolumab
* Ipilimumab
 | First-line treatment:* Bevacizumab with atezolizumab (advanced HCC)
* Sorafenib or lenvatinib with bevacizumab

Second-line treatment for advanced HCC):* Atezolizumab and bevacizumab
 |
| **Esophageal Cancer** | * Paclitaxel
 | HER2-targeted therapy:* Trastuzumab
* Trastuzumab deruxtecan

Anti-angiogenesis therapy:* Ramucirumab
 | Anti-PD-1 antibodies:* Pembrolizumab
* Nivolumab
 |  |
| **Gastric cancer****Gastric cancer** | Cisplatin (available as a generic drug)Oxaliplatin Fluorouracil Capecitabine Docetaxel Epirubicin Irinotecan Paclitaxel  | HER2-targeted therapy:* Trastuzumab

Anti-angiogenesis therapy:* Ramucirumab
 | Anti-PD-1 antibodies:* Pembrolizumab
 |  |